- Home
- GFAI vs NERV Comparison
GFAI vs NERV Comparison
Compare GFAI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFAI
- NERV
- Stock Information
- Founded
- GFAI 2018
- NERV 2007
- Country
- GFAI Singapore
- NERV United States
- Employees
- GFAI N/A
- NERV N/A
- Industry
- GFAI Diversified Commercial Services
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- GFAI Consumer Discretionary
- NERV Health Care
- Exchange
- GFAI Nasdaq
- NERV Nasdaq
- Market Cap
- GFAI 18.2M
- NERV 16.0M
- IPO Year
- GFAI N/A
- NERV 2014
- Fundamental
- Price
- GFAI $2.04
- NERV $2.11
- Analyst Decision
- GFAI Strong Buy
- NERV Hold
- Analyst Count
- GFAI 2
- NERV 1
- Target Price
- GFAI $6.75
- NERV $5.00
- AVG Volume (30 Days)
- GFAI 7.3M
- NERV 36.3K
- Earning Date
- GFAI 01-01-0001
- NERV 02-20-2025
- Dividend Yield
- GFAI N/A
- NERV N/A
- EPS Growth
- GFAI N/A
- NERV N/A
- EPS
- GFAI N/A
- NERV N/A
- Revenue
- GFAI $35,841,743.00
- NERV N/A
- Revenue This Year
- GFAI $0.37
- NERV N/A
- Revenue Next Year
- GFAI $5.60
- NERV N/A
- P/E Ratio
- GFAI N/A
- NERV N/A
- Revenue Growth
- GFAI 1.78
- NERV N/A
- 52 Week Low
- GFAI $0.94
- NERV $2.03
- 52 Week High
- GFAI $4.30
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- GFAI 55.04
- NERV 42.63
- Support Level
- GFAI $1.73
- NERV $2.10
- Resistance Level
- GFAI $2.12
- NERV $2.39
- Average True Range (ATR)
- GFAI 0.48
- NERV 0.12
- MACD
- GFAI -0.02
- NERV -0.01
- Stochastic Oscillator
- GFAI 26.69
- NERV 21.62
About GFAI Guardforce AI Co. Limited
Guardforce AI Co Ltd is a provider of cash solutions and cash handling services located in Thailand. The company engages in the cash logistics business, and its services include cash-in-transit, or CIT, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions (cash deposit management and express cash service). Its customers include local commercial banks, chain retailers, coin-manufacturing mints, and government authorities.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.